focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
@Welsh - you are a sanctimonious git.
Climb down off that pedestal you put yourself on. You are not superior to other investors who have made an enquiry to a PR company of a share they are invested in. I am in this for the long term, but have a query about the wording in an RNS 3 weeks ago. End of.
And just to add Welsh, I work for a business where we get enquiries from investors. I don’t accuse them of being traders when they ask a question of the Managers. We would respond to their query / address their concerns. Especially if something we had told them was unclear. STRONG BUY!
No - I agree RM has more important things to do, which is why I didn’t email him. I emailed the PR company and had a slight dig at them. And requested they pass on the sentiment about more/clearer communications next time they speak.
Just to make it clear to foodforthought, I rate this stock A STRONG BUY (despite the funny definition of imminently).
The problem- as I mentioned below - and has been discussed on here A LOT is the definition of imminently. Usually you would expect a first dose RNS. So if P3 has started then that would be a nice surprise- however, if it has not then that is a funny definition of imminently, so an explanation would be good. It should be bleeding obvious from my messages that I am a big supporter of sng and a believer in the science - but if a number of investors are confused by details in the RNS three weeks ago, then a further update is required (and there are many I assume because of the number of recommendations for the initial post). Maybe next time they will be a little more specific in the RNS / provide more detail / follow up with an interview which gives more information - and that can only be a good thing.
I am happy with my investment and am a staunch supporter of sng. Check all my previous posts and my “Strong buy” opinion on every one. But it doesn’t mean that things cannot be improved with more/better communication.
But
Food - yes, and normally I would be satisfied with that. But - as discussed here on many occasions- they did say in that update: “Phase III trial to commence dosing in UK imminently“
So, a bit more detail with regards to timing of P3 and/or an explanation of why it has not started (e.g. if they said the changes to the trial delayed the start but should speed up the end results and analysis I would be happy).
As I hinted in my note, at this crucial stage more PR is important to keep investors happy and help prevent the attack of the undead/trolls like we had on this Board last night.
Dear Sir/Madam,
As an investor in SNG, myself and a number of other investors are concerned about the lack of information provided by the company at present. While we understand staff at Synairgen will be incredibly busy - there is a great deal of uncertainty regarding progress of the Phase 3 trial - which was said would start in Q4 2020.
It would be good to update investors on progress on this front and also progress on the home trial.
With announcements from the government yesterday about new COVID drugs, there is a worry that Synairgen will be left behind - without regular PR and communications with investors and the wider medical community, reminding them that SNG is one of the more promising drugs being trialled. Any communication may at the same time serve to promote the home trial - where I gather take-up has been slow.
While it is pleasing that vaccines and alternative drugs are becoming available to help solve this crisis - we have invested in Synairgen as we believe it will prove to be one of the best options out there, and we are keen that it fulfills its potential, and does not get overlooked.
I expect the usual bland response from Consillium, as I appreciate you cannot give out any market sensitive information - however, I would appreciate that in your next conversation with Synairgen, you pass on the sentiment about increasing the level of PR at this crucial stage.
Kind regards,
Xxxx
I have now filtered you - but if you’re reading this, I genuinely think you need to get some help.
Often I would have a swipe at people disrupting the board - but I don’t think it would do any good in your case. Please go and speak to a therapist for your own good.
Have none of you derampers on here heard of the ‘flu?! Just to spell out the bleedin’ obvious for some of you (Dacorum) - every year there is a new vaccine for the flu. It didn’t magically disappear when the first flu vaccine was administered. And FYI, it wasn’t administered to everyone in the world simultaneously, hence it mutates.
So, if you are a muppet and believe the flu doesn’t exist, then you might believe BS spouted by Dacorum and sell your shares. Otherwise you should hold.
Have suddenly become panic buyers. Everyone was expecting the AZN vaccine to be approved in UK. I hope it is successful here - but I think US and Europe are (rightly) a bit suspicious of the numbers being put out.
No need to panic as there is plenty of SNG still required in this country and across the globe. Especially if countries decide to stockpile assuming new strains etc. Hold for interferon gold.
Unless KC pulls a rabbit out the hat he was wrong about a pre-Christmas update. However, all is good with EMH. SP is heading in the right direction and that should continue throughout 2021 as progress towards developing the largest lithium mine in Europe continues, in a sector with strong fundamentals, and news of offtakes to come. I expect this to be at least double where it is now within 6 months. Hold for gold/lithium. HNY all.
I saw the potential of this share a long time ago. I just invested 4-5 years too early! Wish I’d been in a position to load up in the summer too. Plenty more to come here - there should be a steady rise up and over £1 in the next 3-6m with a few peaks and troughs in the meantime.